Liraglutide’s Future Uncertain: Panel Voices Concern Over Cancer And CV Risk

Approval of Novo Nordisk's Victoza (liraglutide) for type 2 diabetes hinges on FDA's comfort with a safety database lacking on two fronts, an agency panel said April 2

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet